儿童部分厚度烧伤银敷料成本效果分析
该研究基于随机对照试验,从医疗提供者视角对三种银敷料治疗0-15岁儿童≤10%TBSA部分厚度烧伤进行成本效果分析,以完全上皮化天数为健康结局。结果显示Mepilex Ag™组成本显著低于Acticoat™和Acticoat™联合Mepitel™组,且Mepilex Ag™成为优势方案的概率分别为99%和97%。结论推荐Mepilex Ag™用于该人群。
要点
- Mepilex Ag™组中位成本94.45澳元,低于Acticoat™组244.90澳元和联合组196.66澳元。
- Mepilex Ag™相比Acticoat™和联合组的优势概率分别为99%和97%。
- 联合组相比Acticoat™的优势概率82%,但受植皮手术影响敏感。
核心结论
- Mepilex Ag™在儿童≤10%TBSA部分厚度烧伤治疗中为优势敷料选择。
研究设计与样本
- 基于随机对照试验的经济学评价,纳入96名0-15岁儿童,比较Acticoat™、Acticoat™联合Mepitel™和Mepilex Ag™三种敷料。
- 从医疗提供者视角进行增量成本效果分析,成本收集自2013年3月至2014年7月及上皮化后一年时间跨度。
主要发现
- Mepilex Ag™组中位成本为94.45澳元,Acticoat™组为244.90澳元,联合组为196.66澳元。
- Mepilex Ag™优于Acticoat™的概率为99%,优于联合组的概率为97%。
- 联合组优于Acticoat™的概率为82%,但该概率对植皮手术效应敏感。
关键数值与推荐
- 成本包括敷料、人力、镇痛和瘢痕管理相关费用。
- 健康结局指标为完全伤口上皮化天数。
临床怎么用
- 对于儿童≤10%TBSA部分厚度烧伤,可优先选择Mepilex Ag™以降低医疗成本并提高效果。
局限性
- 经济学评价基于单次试验数据,植皮手术等低频高成本事件可能影响结果稳定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Partial thickness burns of up to 10% total body surface area (TBSA) in children are common injuries primarily treated in the outpatient setting using expensive silver-containing dressings. However, economic evaluations in the paediatric burns population are lacking to assist healthcare providers when choosing which dressing to use. The aim of this study was to conduct a cost-effectiveness analysis of three silver dressings for partial thickness burns ≤10% TBSA in children aged 0-15 years using days to full wound re-epithelialization as the health outcome. METHOD: This study was a trial based economic evaluation (incremental cost effectiveness) conducted from a healthcare provider perspective. Ninety-six children participated in the trial investigating Acticoat™, Acticoat™ with Mepitel™ or Mepilex Ag™. Costs directly related to the management of partial thickness burns ≤10% TBSA were collected during the trial from March 2013 to July 2014 and for a one year after re-epithelialization time horizon. Incremental cost effectiveness ratios were estimated and dominance probabilities calculated from bootstrap resampling trial data. Sensitivity analyses were conducted to examine the potential effect of accounting for infrequent, but high cost, skin grafting surgical procedures. RESULTS: Costs (dressing, labour, analgesics, scar management) were considerably lower in the Mepilex Ag™ group (median AUD$94.45) compared to the Acticoat™ (median $244.90) and Acticoat™ with Mepitel™ (median $196.66) interventions. There was a 99% and 97% probability that Mepilex Ag™ dominated (cheaper and more effective than) Acticoat™ and Acticoat™ with Mepitel™, respectively. This pattern of dominance was consistent across raw cost and effects, after a priori adjustments, and sensitivity analyses. There was an 82% probability that Acticoat™ with Mepitel dominated Acticoat™ in the primary analysis, although this probability was sensitive to the effect of skin graft procedures. CONCLUSION: This economic evaluation has demonstrated that Mepilex Ag™ was the dominant dressing choice over both Acticoat™ and Acticoat™ with Mepitel™ in this trial-based economic evaluation and is recommended for treatment of paediatric partial thickness burns ≤10% TBSA.
引用
- Gee Kee E, Stockton K, Kimble RM, et al. Cost-effectiveness of silver dressings for paediatric partial thickness burns: An economic evaluation from a randomized controlled trial. Burns. 2017. PMID: 28408145. doi:10.1016/j.burns.2016.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。